Assessing Bioavailability Enabling Technologies using Upperton Pharma Solutions Screening Platform – UpperSolv™+
Currently approximately 9 out of 10 new drugs entering clinical trials will fail before reaching approval. Many of these drugs will fail due to problems with ADME (absorption, distribution, metabolism and excretion) rather than lack of efficacy. One of the more common issues associated with ADME is the need for increasing bioavailability. Therefore, it is … Read more